NIH ACTIV vaccine working group weighs role of human challenge studies for SARS-CoV-2 vaccine development

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).

 

07/01/2020 05:00 PM EDT

The authors conclude that large, randomized, controlled trials of SARS-CoV-2 are the fastest and most effective path forward for establishing vaccine safety and efficacy.